Figures computed from official regulatory filings — .
Analysttarget 5.33 USD (-69%) · consensus 3/5 · 0 buy · 1 hold · 0 sell
Ownershipinsiders 1.73% · institutions 4.04% · short 6.3% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Tracon Pharmaceuticals, Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody that is in Phase I clinical trial for the treatment of various cancer indications. The company's clinical stage products also include TRC102, a small molecule that is in Phase II clinical trial for the treatment of mesothelioma, and in Phase I clinical trial to treat solid tumors, lung cancer, and glioblastoma; and TJ004309, a CD73 antibody that is in Phase I clinical development for the treatment of solid tumors. In addition, it is developing bispecific antibodies, which are in preclinical stage. It has collaboration and license agreements with 3D Medicines Co., Ltd. and Jiangsu Alphamab Biopharmaceuticals Co., Ltd. for the development of envafolimab; I-Mab Biopharma for the development of CD73 antibody TJ004309 and bispecific antibodies; and cooperative research and development agreement with National Cancer Institute. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in San Diego, California.
Market information source · Oct 5, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 5, 2026
Open-market timeline · full history
196 buys55 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| THEUER CHARLEStrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) |
| THEUER CHARLEStrack record | Award | $490 | SEC |
| Brown Scott B.track record | Award | $490 | SEC |
| Brown Scott B.track record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| THEUER CHARLEStrack record | Award | $455 | Unusual size | SEC |
| Opaleye Management Inc.track record | Sell | $1.3M | Unusual size | SEC |
| Opaleye Management Inc.track record | Sell | $127.6K | SEC |
| THEUER CHARLEStrack record | Buy | $35.3K | conv 60Unusual size | SEC |
| THEUER CHARLEStrack record | Buy | $2.6K | conv 33 | SEC |
| PELLETIER SAUNDRA Ltrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| LARUE WILLIAM R | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Johnson-Pratt Lisa | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Twiford J Rainer | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| MATTINGLY MARTIN A | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| WORLAND STEPHEN Ttrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Lam Carol C. | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Opaleye Management Inc.track record | Buy | $240.8K | conv 25Cluster | SEC |
| THEUER CHARLEStrack record | Buy | $7.3K | conv 25Cluster | SEC |
| THEUER CHARLEStrack record | Buy | $304 | conv 26Cluster | SEC |
| Adams Bonne J. | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| THEUER CHARLEStrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Brown Scott B.track record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| LARUE WILLIAM R | Sell | $151.2 | SEC |
| THEUER CHARLEStrack record | Buy | $11K | conv 38Cluster | SEC |
| Brown Scott B.track record | Buy | $5.2K | conv 54Cluster | SEC |